TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

TrYbe (R) is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long in vivo half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable 'reach' properties. We demonstrate the format's broad functionality by co-targeting of soluble and cell surface antigens. The benefit of monovalent target binding is illustrated by the lack of formation of large immune complexes when co-targeting multivalent antigens. TrYbes (R) are manufactured using standard mammalian cell culture and protein A affinity capture processes. TrYbes (R) have been formulated at high concentrations and have favorable drug-like properties, including stability, solubility, and low viscosity. The unique functionality and inherent developability of the TrYbe (R) makes it a promising multi-specific antibody fragment format for antibody therapy.